222 related articles for article (PubMed ID: 32294439)
1. Hotspots of Aberrant Enhancer Activity in Fibrolamellar Carcinoma Reveal Candidate Oncogenic Pathways and Therapeutic Vulnerabilities.
Dinh TA; Sritharan R; Smith FD; Francisco AB; Ma RK; Bunaciu RP; Kanke M; Danko CG; Massa AP; Scott JD; Sethupathy P
Cell Rep; 2020 Apr; 31(2):107509. PubMed ID: 32294439
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-375 Suppresses the Growth and Invasion of Fibrolamellar Carcinoma.
Dinh TA; Jewell ML; Kanke M; Francisco A; Sritharan R; Turnham RE; Lee S; Kastenhuber ER; Wauthier E; Guy CD; Yeung RS; Lowe SW; Reid LM; Scott JD; Diehl AM; Sethupathy P
Cell Mol Gastroenterol Hepatol; 2019; 7(4):803-817. PubMed ID: 30763770
[TBL] [Abstract][Full Text] [Related]
3. BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA.
Hirsch TZ; Negulescu A; Gupta B; Caruso S; Noblet B; Couchy G; Bayard Q; Meunier L; Morcrette G; Scoazec JY; Blanc JF; Amaddeo G; Nault JC; Bioulac-Sage P; Ziol M; Beaufrère A; Paradis V; Calderaro J; Imbeaud S; Zucman-Rossi J
J Hepatol; 2020 May; 72(5):924-936. PubMed ID: 31862487
[TBL] [Abstract][Full Text] [Related]
4. Unique genomic profile of fibrolamellar hepatocellular carcinoma.
Cornella H; Alsinet C; Sayols S; Zhang Z; Hao K; Cabellos L; Hoshida Y; Villanueva A; Thung S; Ward SC; Rodriguez-Carunchio L; Vila-Casadesús M; Imbeaud S; Lachenmayer A; Quaglia A; Nagorney DM; Minguez B; Carrilho F; Roberts LR; Waxman S; Mazzaferro V; Schwartz M; Esteller M; Heaton ND; Zucman-Rossi J; Llovet JM
Gastroenterology; 2015 Apr; 148(4):806-18.e10. PubMed ID: 25557953
[TBL] [Abstract][Full Text] [Related]
5. Multiomic analysis of microRNA-mediated regulation reveals a proliferative axis involving miR-10b in fibrolamellar carcinoma.
Francisco AB; Kanke M; Massa AP; Dinh TA; Sritharan R; Vakili K; Bardeesy N; Sethupathy P
JCI Insight; 2022 Jun; 7(11):. PubMed ID: 35482409
[TBL] [Abstract][Full Text] [Related]
6. β-catenin cancer-enhancing genomic regions axis is involved in the development of fibrolamellar hepatocellular carcinoma.
Gulati R; Johnston M; Rivas M; Cast A; Kumbaji M; Hanlon MA; Lee S; Zhou P; Lake C; Schepers E; Min KW; Yoon JH; Karns R; Reid LM; Lopez-Terrada D; Timchenko L; Parameswaran S; Weirauch MT; Ranganathan S; Bondoc A; Geller J; Tiao G; Shin S; Timchenko N
Hepatol Commun; 2022 Oct; 6(10):2950-2963. PubMed ID: 36000549
[TBL] [Abstract][Full Text] [Related]
7. Methylome sequencing for fibrolamellar hepatocellular carcinoma depicts distinctive features.
Malouf GG; Tahara T; Paradis V; Fabre M; Guettier C; Yamazaki J; Long H; Lu Y; Raynal NJ; Jelinek J; Mouawad R; Khayat D; Brugières L; Raymond E; Issa JP
Epigenetics; 2015; 10(9):872-81. PubMed ID: 26224146
[TBL] [Abstract][Full Text] [Related]
8. Fibrolamellar carcinomas show overexpression of genes in the RAS, MAPK, PIK3, and xenobiotic degradation pathways.
Kannangai R; Vivekanandan P; Martinez-Murillo F; Choti M; Torbenson M
Hum Pathol; 2007 Apr; 38(4):639-44. PubMed ID: 17367606
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of The Cancer Genome Atlas reveals a unique gene and non-coding RNA signature of fibrolamellar carcinoma.
Dinh TA; Vitucci EC; Wauthier E; Graham RP; Pitman WA; Oikawa T; Chen M; Silva GO; Greene KG; Torbenson MS; Reid LM; Sethupathy P
Sci Rep; 2017 Mar; 7():44653. PubMed ID: 28304380
[TBL] [Abstract][Full Text] [Related]
10. Transcriptional dysregulation by aberrant enhancer activation and rewiring in cancer.
Okabe A; Kaneda A
Cancer Sci; 2021 Jun; 112(6):2081-2088. PubMed ID: 33728716
[TBL] [Abstract][Full Text] [Related]
11. Single-Cell RNA Sequencing Identifies Yes-Associated Protein 1-Dependent Hepatic Mesothelial Progenitors in Fibrolamellar Carcinoma.
Jewell ML; Gibson JR; Guy CD; Hyun J; Du K; Oh SH; Premont RT; Hsu DS; Ribar T; Gregory SG; Diehl AME
Am J Pathol; 2020 Jan; 190(1):93-107. PubMed ID: 31669305
[TBL] [Abstract][Full Text] [Related]
12. HSCs-derived COMP drives hepatocellular carcinoma progression by activating MEK/ERK and PI3K/AKT signaling pathways.
Li Q; Wang C; Wang Y; Sun L; Liu Z; Wang L; Song T; Yao Y; Liu Q; Tu K
J Exp Clin Cancer Res; 2018 Sep; 37(1):231. PubMed ID: 30231922
[TBL] [Abstract][Full Text] [Related]
13. Molecular profiling and analysis of genetic aberrations aimed at identifying potential therapeutic targets in fibrolamellar carcinoma of the liver.
El Dika I; Bowman AS; Berger MF; Capanu M; Chou JF; Benayed R; Zehir A; Shia J; O'Reilly EM; Klimstra DS; Solit DB; Abou-Alfa GK
Cancer; 2020 Sep; 126(18):4126-4135. PubMed ID: 32663328
[TBL] [Abstract][Full Text] [Related]
14. LINC00978 promotes hepatocellular carcinoma carcinogenesis partly via activating the MAPK/ERK pathway.
Zhang Q; Cheng S; Cao L; Yang J; Wang Y; Chen Y
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32077915
[TBL] [Abstract][Full Text] [Related]
15. Identification of Long Non-Coding RNA Profiles and Potential Therapeutic Agents for Fibrolamellar Carcinoma Based on RNA-Sequencing Data.
Kim J; Kim Y; Lee B
Genes (Basel); 2023 Aug; 14(9):. PubMed ID: 37761849
[TBL] [Abstract][Full Text] [Related]
16. Oncogene-dependent addiction to carbohydrate-responsive element binding protein in hepatocellular carcinoma.
Ribback S; Che L; Pilo MG; Cigliano A; Latte G; Pes GM; Porcu A; Pascale RM; Li L; Qiao Y; Dombrowski F; Chen X; Calvisi DF
Cell Cycle; 2018; 17(12):1496-1512. PubMed ID: 29965794
[TBL] [Abstract][Full Text] [Related]
17. An acquired scaffolding function of the DNAJ-PKAc fusion contributes to oncogenic signaling in fibrolamellar carcinoma.
Turnham RE; Smith FD; Kenerson HL; Omar MH; Golkowski M; Garcia I; Bauer R; Lau HT; Sullivan KM; Langeberg LK; Ong SE; Riehle KJ; Yeung RS; Scott JD
Elife; 2019 May; 8():. PubMed ID: 31063128
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide DNA methylation and hydroxymethylation analysis reveal human menstrual blood-derived stem cells inhibit hepatocellular carcinoma growth through oncogenic pathway suppression via regulating 5-hmC in enhancer elements.
Wu Y; Chen X; Zhao Y; Wang Y; Li Y; Xiang C
Stem Cell Res Ther; 2019 May; 10(1):151. PubMed ID: 31151404
[TBL] [Abstract][Full Text] [Related]
19. Targeting of noncoding RNAs encoded by a novel MYC enhancers inhibits the proliferation of human hepatic carcinoma cells in vitro.
Choi HI; An GY; Yoo E; Baek M; Chai JC; Binas B; Lee YS; Jung KH; Chai YG
Sci Rep; 2022 Jan; 12(1):855. PubMed ID: 35039581
[TBL] [Abstract][Full Text] [Related]
20. Long non-coding RNA LINC01503 promotes the progression of hepatocellular carcinoma via activating MAPK/ERK pathway.
Wang MR; Fang D; Di MP; Guan JL; Wang G; Liu L; Sheng JQ; Tian DA; Li PY
Int J Med Sci; 2020; 17(9):1224-1234. PubMed ID: 32547318
[No Abstract] [Full Text] [Related]
[Next] [New Search]
